Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have identified neural crosstalk as the mechanism that drives widespread inflammation in inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and atherosclerosis.
The U.S. Food and Drug Administration issued a Complete Response Letter to UCB regarding the Belgium-based company’s Biologics License Application for bimekizumab for adults with moderate to severe plaque psoriasis.
The U.S. Food and Drug Administration approved AbbVie’s Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts 30 percent of patients with psoriasis.
A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.
Eli Lilly announced that the company’s psoriasis drug Taltz overcame Johnson & Johnson’s Tremfya in a head-to-head study.
The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.
Celgene Corp. – which is being bought by Bristol-Myers Squibb Co. – reported a better-than-expected fourth-quarter 2018 profit, driven mainly by higher sales of the psoriasis drug Otezla.
Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.
Johnson & Johnson reported better-than-expected fourth-quarter revenue, helped by strong demand for the company’s drugs to treat cancer and psoriasis.